Noven Pharmaceuticals, Inc. FDA Inspection Record

FEI 1000222037 · Inspections, Form 483s, warning letters and import refusals

Noven Pharmaceuticals, Inc. is an FDA-registered facility (FEI 1000222037) located in Miami, FL, US. Registered operations: ANALYSIS; LABEL; MANUFACTURE; PACK. RegDataLab tracks 9 FDA inspections and 1 compliance action at this facility.

What FDA found at this site

Latest inspection
Aug 24, 2026: Voluntary Action Indicated (VAI)
Inspections on record
9 (1 OAI, 4 VAI, 4 NAI)
Last OAI inspection
Jul 10, 2015
Warning letters
1 listed by FDA for this FEI, latest Aug 5, 2016
Recalls as the recalling firm
24, latest Oct 31, 2024
Import refusals
2

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Aug 24, 2026Voluntary Action Indicated (VAI)Backup file not maintained (21 CFR 211.68(b))
input/output verification (21 CFR 211.68(b))
Identity Testing of Each Component (21 CFR 211.84(d)(1))
Second person sign off (21 CFR 211.194(a)(8))
Feb 13, 2026No Action Indicated (NAI)No citations listed
Nov 17, 2021Voluntary Action Indicated (VAI)No citations listed
Jan 26, 2018Voluntary Action Indicated (VAI)No citations listed
Jul 10, 2015Official Action Indicated (OAI)No citations listed
Sep 24, 2012No Action Indicated (NAI)No citations listed
Jun 4, 2012No Action Indicated (NAI)No citations listed
May 6, 2010Voluntary Action Indicated (VAI)Written procedures not established/followed (21 CFR 211.67(b))
Calibration/Inspection/Checking not done (21 CFR 211.68(a))
Absence of Written Procedures (21 CFR 211.100(a))
Procedures To Be in Writing (21 CFR 211.80(a))
and 2 more
Feb 6, 2009No Action Indicated (NAI)Procedures not in writing, fully followed (21 CFR 211.22(d))
Absence of Written Procedures (21 CFR 211.100(a))
Investigations of discrepancies, failures (21 CFR 211.192)
Complaint Handling Procedure (21 CFR 211.198(a))
and 5 more

Recalls

Showing the 10 most recent of 24 recalls. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Oct 31, 2024Class IID-0055-2025Xelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 hours, 30…
Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).
Mar 10, 2023Class IID-0470-2023Daytrana (methylphenidate transdermal system) CII, 10mg, 30-count carton, Rx only… and 3 more products
Defective Delivery System: Out of specification for shear.
Nov 16, 2022Class IID-0071-2023Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours, (1.6 mg/hr)…
Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive…
Jun 24, 2022Class IID-1169-2022Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr)…
Defective Delivery System: Customer complaints received for ripping patches and tight release/adhesive transfer.
May 6, 2022Class IID-0889-2022Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr)…
Defective Delivery System: customer complaints exceeded respective action limits.
Jul 30, 2021Class IID-0724-2021Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day… and 1 more product
Failed Stability Specifications; out of specification for shear.
May 20, 2021Class IID-0393-2021Daytrana (methylphenidate transdermal system), Delivers 10 mg over 9 hours (1.1 mg/hr), 30… and 1 more product
Defective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the…
Apr 16, 2021Class IID-0336-2021Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only… and 1 more product
Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the…
Feb 19, 2021Class IID-0293-2021Daytrana (methylphenidate transdermal system), Delivers 10 mg over 9 hours (1.1 mg/hr)… and 3 more products
Defective Delivery System: Out of specification for mechanical peel.
Mar 31, 2020Class IID-1247-2020Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr)… and 2 more products
Defective Delivery System: Out of specification for mechanical peel and shear.

FDA record score

33 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 17, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

29 records behind this number
RecordDatePoints x age weightAdds
Inspection classified VAIAug 24, 20266 x 16
Inspection classified VAINov 17, 20216 x 0.63.6
Class II recall D-0055-2025, this FEI as the recalling firmOct 31, 20244 x 0.62.4
Class II recall D-0470-2023, this FEI as the recalling firmMar 10, 20234 x 0.62.4
Class II recall D-0071-2023, this FEI as the recalling firmNov 16, 20224 x 0.62.4
Class II recall D-1169-2022, this FEI as the recalling firmJun 24, 20224 x 0.62.4
Class II recall D-0889-2022, this FEI as the recalling firmMay 6, 20224 x 0.62.4
Inspection classified VAIJan 26, 20186 x 0.251.5
Class II recall D-0724-2021, this FEI as the recalling firmJul 30, 20214 x 0.251
Class II recall D-0393-2021, this FEI as the recalling firmMay 20, 20214 x 0.251
Class II recall D-0336-2021, this FEI as the recalling firmApr 16, 20214 x 0.251
Class II recall D-0293-2021, this FEI as the recalling firmFeb 19, 20214 x 0.251
Class II recall D-1247-2020, this FEI as the recalling firmMar 31, 20204 x 0.251
Class II recall D-1042-2020, this FEI as the recalling firmMar 2, 20204 x 0.251
Class II recall D-1207-2018, this FEI as the recalling firmSep 7, 20184 x 0.251
Class II recall D-0862-2018, this FEI as the recalling firmMay 4, 20184 x 0.251
Class II recall D-0627-2018, this FEI as the recalling firmApr 9, 20184 x 0.251
Class II recall D-1169-2017, this FEI as the recalling firmAug 30, 20174 x 0.251
Class II recall D-0428-2017, this FEI as the recalling firmAug 22, 201610 years or older, so it adds no points0
Warning letter on FDA's dashboard, which does not show close-outsAug 5, 201610 years or older, so it adds no points0
Class II recall D-1438-2016, this FEI as the recalling firmDec 21, 201510 years or older, so it adds no points0
Class II recall D-0008-2016, this FEI as the recalling firmJul 27, 201510 years or older, so it adds no points0
Inspection classified OAIJul 10, 201510 years or older, so it adds no points0
Class II recall D-1608-2014, this FEI as the recalling firmJul 15, 201410 years or older, so it adds no points0
Class II recall D-1171-2014, this FEI as the recalling firmFeb 13, 201410 years or older, so it adds no points0
Class II recall D-312-2013, this FEI as the recalling firmJan 31, 201310 years or older, so it adds no points0
Class II recall D-1653-2012, this FEI as the recalling firmJul 12, 201210 years or older, so it adds no points0
Class II recall D-1413-2012, this FEI as the recalling firmMar 22, 201210 years or older, so it adds no points0
Inspection classified VAIMay 6, 201010 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 17, 2026Newest record Nov 9, 2026Current
Inspection citationsNov 17, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 17, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 17, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 17, 2026Newest record Nov 16, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Noven Pharmaceuticals, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Noven Pharmaceuticals, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Noven Pharmaceuticals, Inc.
Location
Miami, FL (US)
Registration Expires
Dec 31, 2027
Operations
ANALYSIS; LABEL; MANUFACTURE; PACK
Source
decrs

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.